Kalytera Therapeutics acquires Talent Biotechs and its programme for cannabidiol pharmaceuticals,

Kalytera Therapeutics, Inc. announced that it has successfully completed the previously announced acquisition of Talent Biotechs Ltd., strengthening Kalytera�s position as an emerging market leader in cannabidiol (�CBD�) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (�GvHD�). Multiple studies have demonstrated that CBD, a non-psychoactive cannabis constituent, possesses remarkable therapeutic potential across a broad range of diseases and disorders. The acquisition of Talent and its late-stage GvHD program significantly advances Kalytera�s position as in CBD pharmaceuticals.